文献速递系统性红斑狼疮

SLE疾病活动度评分(SLE-DAS)的推导与验证:一种对疾病活动变化高敏感的新型SLE连续测量工具

Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity.
PubMed 文献 · Ann Rheum Dis · 2019-01-09

本研究基于两个三级中心520例SLE患者推导并验证了包含17项指标的SLE-DAS。SLE-DAS与PGA(r=0.875)和SLEDAI-2K(r=0.943)高度相关,识别临床有意义变化的最佳ΔSLE-DAS切点为1.72,对改善和恶化的敏感性均显著高于SLEDAI-2K(变化≥4),且特异性相似,在预测损伤累积方面表现更优。

要点

  • SLE-DAS包含17项指标,与PGA和SLEDAI-2K高度相关。
  • 识别临床有意义变化的最佳ΔSLE-DAS切点为1.72。
  • SLE-DAS对改善和恶化的敏感性高于SLEDAI-2K(变化≥4),特异性相似。

核心结论

  • SLE-DAS具有良好的结构效度,在识别疾病活动临床显著变化和预测损伤累积方面优于SLEDAI-2K。

研究设计与样本

  • 研究纳入两个三级中心的520例SLE患者,分为推导队列和验证队列,每次访视使用PGA和SLEDAI-2K评估疾病活动度。
  • 在推导队列中以PGA为因变量采用多变量线性回归构建SLE-DAS,并在验证队列中验证其与PGA和SLEDAI-2K的相关性、识别ΔPGA≥0.3的效能及预测损伤累积的准确性。

主要发现

  • 最终SLE-DAS工具包含17项。
  • 在验证队列中,SLE-DAS与PGA高度相关(r=0.875,p<0.0005),与SLEDAI-2K高度相关(r=0.943,p<0.0005)。
  • 识别临床有意义变化的最佳ΔSLE-DAS切点为1.72。
  • 在验证队列中,SLE-DAS检测临床有意义改善的敏感性高于SLEDAI-2K(变化≥4)(89.5% vs 47.4%,p=0.008),检测恶化的敏感性也更高(95.5% vs 59.1%,p=0.008),同时保持相似的特异性。
  • SLE-DAS在预测损伤累积方面表现优于SLEDAI-2K。

关键数值与推荐

  • SLE-DAS包含17项指标。
  • SLE-DAS与PGA的相关系数r=0.875(p<0.0005),与SLEDAI-2K的相关系数r=0.943(p<0.0005)。
  • 识别临床有意义变化的最佳ΔSLE-DAS切点为1.72。
  • SLE-DAS检测改善的敏感性89.5% vs SLEDAI-2K(变化≥4)47.4%(p=0.008),检测恶化的敏感性95.5% vs 59.1%(p=0.008),特异性相似。

临床怎么用

  • SLE-DAS可作为SLE疾病活动度的连续测量工具,对疾病活动变化敏感,有助于临床识别有意义的改善或恶化。
  • SLE-DAS在预测损伤累积方面优于SLEDAI-2K,可用于评估疾病活动对长期损伤的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To derive and validate a new disease activity measure for systemic lupus erythematosus (SLE), the SLE Disease Activity Score (SLE-DAS), with improved sensitivity to change as compared with SLE Disease Activity Index (SLEDAI), while maintaining high specificity and easiness of use. METHODS: We studied 520 patients with SLE from two tertiary care centres (derivation and validation cohorts). At each visit, disease activity was scored using the Physician Global Assessment (PGA) and SLEDAI 2000 (SLEDAI-2K). To construct the SLE-DAS, we applied multivariate linear regression analysis in the derivation cohort, with PGA as dependent variable. The formula was validated in a different cohort through the study of: (1) correlations between SLE-DAS, PGA and SLEDAI-2K; (2) performance of SLEDAI-2K and SLE-DAS in identifying a clinically meaningful change in disease activity (ΔPGA≥0.3); and (3) accuracy of SLEDAI-2K and SLE-DAS time-adjusted means in predicting damage accrual. RESULTS: The final SLE-DAS instrument included 17 items. SLE-DAS was highly correlated with PGA (r=0.875, p<0.0005) and SLEDAI-2K (r=0.943, p<0.0005) in the validation cohort. The optimal discriminative ΔSLE-DAS cut-off to detect a clinically meaningful change was 1.72. In the validation cohort, SLE-DAS showed a higher sensitivity than SLEDAI-2K (change ≥4) to detect a clinically meaningful improvement (89.5% vs 47.4%, p=0.008) or worsening (95.5% vs 59.1%, p=0.008), while maintaining similar specificities. SLE-DAS performed better in predicting damage accrual than SLEDAI-2K. CONCLUSION: SLE-DAS has a good construct validity and has better performance than SLEDAI-2K in identifying clinically significant changes in disease activity and in predicting damage accrual.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Jesus D, Matos A, Henriques C, et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis. 2019. PMID: 30626657. doi:10.1136/annrheumdis-2018-214502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。